NCT06007456

Brief Summary

Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16. The term JIA is an umbrella that includes very different diseases. The current International League of Associations for Rheumatology (ILAR) classification divides JIA patients into 7 categories based on number of involved joints and time of involvement, presence of systemic symptoms, psoriatic findings and spondyloarthritis. This classification groups together patients with different disease and divides patients with the same disease. In the first case, unifying distinct diseases could lead to undifferentiated therapeutic choices, moving away from the modern concept of therapeutic personalization. In the second case, similarities between paediatric and adult arthritis could not be found. This involves both a loss of collaboration with the adult rheumatologist and the difficulty in accessing possibly effective therapies approved only for adult arthritis. In clinical practice, it is increasingly evident that the number of affected joints and the speed of joint involvement are not useful criteria for defining the type and severity of disease. Joint counts lead to underestimate the importance of joint distribution in the identification of distinct forms of arthritis. A recent study found that patterns of joint involvement represent prognostic features, so grouping patients by joint pattern and degree of localization may help clinicians tailor treatments based on predicted disease trajectories. Another important point to differentiate some forms of arthritis is the presence of enthesitis and tenosynovitis. Sometimes tendon inflammation can be not clinically evident, so ultrasound evaluation is useful to detect it. Musculoskeletal ultrasound (MSUS) has been used worldwide by adult rheumatologist, but it is beginning a useful tool also in patients with JIA. Recent studies underline the important role of MSUS findings to assess disease activity and assist disease classification. In recent years, the need has emerged to replace the ILAR criteria with a new nomenclature based on the disease biology. This approach could help clinicians to choose a personalized therapeutic strategy for patients with arthritis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2022

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 28, 2023

Completed
5 months until next milestone

First Posted

Study publicly available on registry

August 23, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2024

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2026

Completed
Last Updated

June 14, 2024

Status Verified

June 1, 2024

Enrollment Period

2.7 years

First QC Date

March 28, 2023

Last Update Submit

June 13, 2024

Conditions

Keywords

JIAclassificationtransition of care

Outcome Measures

Primary Outcomes (3)

  • To evaluate disease activity by the Juvenile Arthritis Disease score during the transition to adult care

    The Juvenile Arthritis Disease score (JADAS) includes 4 measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) (0=no activity-10=maximum activity); parent global assessment of well-being, measured on a 0-10 VAS (0=very well-10=very poor); the erythrocyte sedimentation rate, normalized to a 0 to 10 scale; and a count of joints with active disease. The final score is calculated as the sum of the scores of these four components (higher scores indicate higher disease activity).

    Between 14-17 years of age

  • To evaluate disease activity by the Health Assessment Questionnaire - Disability Index during the transition to adult care

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities, with 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8.

    Between 14-17 years of age

  • To assess joint damage by radiological examination during the transition to adult care

    Radiographs will be performed to assess the presence of joint damage

    Between 14-17 years of age

Secondary Outcomes (1)

  • To evaluate non-inflammatory pain by the widespread pain index scale during transition to adult care

    Between 14-17 years of age

Study Arms (2)

Patients at onset of juvenile arthritis

New diagnosis of JIA

Patients with juvenile arthritis in follow up

Subjects with JIA already followed at Rheumatologic Service

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Subjects with JIA during the transition to adult care

You may qualify if:

  • Subjects under the age of 18 years
  • Arthritis persisting for at least 6 weeks with no known cause

You may not qualify if:

  • No consent from the patients' guardians
  • Patients with Systemic onset Juvenile Idiopathic Arthritis
  • Patients who developed arthritis on a pre-existing inflammatory disorder such as Inflammatory Bowel Disease, and had received previous treatments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IRCCS Burlo Garofolo

Trieste, 34137, Italy

RECRUITING

(Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine

Udine, Italy

RECRUITING

MeSH Terms

Conditions

Arthritis, Juvenile

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Serena Pastore, MD

    IRCCS materno infantile Burlo Garofolo

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2023

First Posted

August 23, 2023

Study Start

January 10, 2022

Primary Completion

September 15, 2024

Study Completion

March 15, 2026

Last Updated

June 14, 2024

Record last verified: 2024-06

Locations